BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 30980203)

  • 21. Clinical significance of plasma fibrinogen level as a predictive marker for postoperative recurrence of esophageal squamous cell carcinoma in patients receiving neoadjuvant treatment.
    Matsuda S; Takeuchi H; Fukuda K; Nakamura R; Takahashi T; Wada N; Kawakubo H; Saikawa Y; Omori T; Kitagawa Y
    Dis Esophagus; 2014; 27(7):654-61. PubMed ID: 23980622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pre-treatment maximal oesophageal wall thickness is independently associated with response to chemoradiotherapy in patients with T3-4 oesophageal squamous cell carcinoma.
    Li SH; Rau KM; Lu HI; Wang YM; Tien WY; Liang JL; Lin WC
    Eur J Cardiothorac Surg; 2012 Dec; 42(6):958-64. PubMed ID: 22466694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison between surgery and definitive chemoradiotherapy for patients with resectable esophageal squamous cell carcinoma: a propensity score analysis.
    Nomura M; Oze I; Kodaira T; Abe T; Komori A; Narita Y; Masuishi T; Taniguchi H; Kadowaki S; Ura T; Andoh M; Tachibana H; Uemura N; Tajika M; Niwa Y; Muto M; Muro K
    Int J Clin Oncol; 2016 Oct; 21(5):890-898. PubMed ID: 26980212
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between sarcopenia based on psoas muscle index and the response to nivolumab in metastatic renal cell carcinoma: A retrospective study.
    Ueki H; Hara T; Okamura Y; Bando Y; Terakawa T; Furukawa J; Harada K; Nakano Y; Fujisawa M
    Investig Clin Urol; 2022 Jul; 63(4):415-424. PubMed ID: 35796138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of Skeletal Muscle Mass During Neoadjuvant Chemoradiotherapy Predicts Postoperative Mortality in Esophageal Cancer Surgery.
    Reisinger KW; Bosmans JW; Uittenbogaart M; Alsoumali A; Poeze M; Sosef MN; Derikx JP
    Ann Surg Oncol; 2015 Dec; 22(13):4445-52. PubMed ID: 25893413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant chemoradiotherapy for esophageal carcinoma.
    Zhang X; Watson DI; Jamieson GG; Bessell JR; Devitt PG
    Dis Esophagus; 2005; 18(2):104-8. PubMed ID: 16053485
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between the thoroughness of the histopathological examination and survival in patients with esophageal squamous cell carcinoma who achieve pathological complete response after chemoradiotherapy.
    Chiu CH; Chen WH; Wen YW; Yeh CJ; Chao YK; Chang HK; Tseng CK; Liu YH
    Dis Esophagus; 2016 Aug; 29(6):634-41. PubMed ID: 26175202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma.
    Higuchi I; Yasuda T; Yano M; Doki Y; Miyata H; Tatsumi M; Fukunaga H; Takiguchi S; Fujiwara Y; Hatazawa J; Monden M
    J Thorac Cardiovasc Surg; 2008 Jul; 136(1):205-12, 212.e1-3. PubMed ID: 18603077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of sarcopenia in patients with intrahepatic cholangiocarcinoma: Prognostic marker or hyped parameter?
    Hahn F; Müller L; Stöhr F; Mähringer-Kunz A; Schotten S; Düber C; Bartsch F; Lang H; Galle PR; Weinmann A; Kloeckner R
    Liver Int; 2019 Jul; 39(7):1307-1314. PubMed ID: 31070868
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT
    Tang H; Tan L; Shen Y; Wang H; Lin M; Feng M; Xu S; Guo W; Qian C; Liu T; Zeng Z; Hou Y; Yu Z; Jiang H; Li Z; Chen C; Lian C; Du M; Li H; Xie D; Yin J; Zhao N; Wang Q
    BMC Cancer; 2017 Jun; 17(1):450. PubMed ID: 28659128
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High serum levels of vascular endothelial growth factor-A and transforming growth factor-β1 before neoadjuvant chemoradiotherapy predict poor outcomes in patients with esophageal squamous cell carcinoma receiving combined modality therapy.
    Cheng JC; Graber MS; Hsu FM; Tsai CL; Castaneda L; Lee JM; Chang DT; Koong AC
    Ann Surg Oncol; 2014 Jul; 21(7):2361-8. PubMed ID: 24623035
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient's Skeletal Muscle Radiation Attenuation and Sarcopenic Obesity are Associated with Postoperative Morbidity after Neoadjuvant Chemoradiation and Resection for Rectal Cancer.
    Berkel AEM; Klaase JM; de Graaff F; Brusse-Keizer MGJ; Bongers BC; van Meeteren NLU
    Dig Surg; 2019; 36(5):376-383. PubMed ID: 29898443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Measuring sarcopenia on pre-operative CT in older adults undergoing emergency laparotomy: a comparison of three different calculations.
    Simpson G; Manu N; Magee C; Wilson J; Moug S; Vimalachandran D
    Int J Colorectal Dis; 2020 Jun; 35(6):1095-1102. PubMed ID: 32215679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Comparison between docetaxel plus cisplatin and cisplatin plus fluorouracil in the neoadjuvant chemoradiotherapy for local advanced esophageal squamous cell carcinoma].
    Wu S; Chen MY; Luo JC; Wei L; Chen Z
    Zhonghua Zhong Liu Za Zhi; 2012 Nov; 34(11):873-6. PubMed ID: 23291141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of skeletal muscle mass during neoadjuvant treatments correlates with worse prognosis in esophageal cancer: a retrospective cohort study.
    Järvinen T; Ilonen I; Kauppi J; Salo J; Räsänen J
    World J Surg Oncol; 2018 Feb; 16(1):27. PubMed ID: 29433514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.
    Shridhar R; Hoffe SE; Almhanna K; Weber JM; Chuong MD; Karl RC; Meredith K
    Ann Surg Oncol; 2013 Sep; 20(9):3038-43. PubMed ID: 23625142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pre-operative Sarcopenia Identifies Patients at Risk for Poor Survival After Resection of Biliary Tract Cancers.
    Chakedis J; Spolverato G; Beal EW; Woelfel I; Bagante F; Merath K; Sun SH; Chafitz A; Galo J; Dillhoff M; Cloyd J; Pawlik TM
    J Gastrointest Surg; 2018 Oct; 22(10):1697-1708. PubMed ID: 29855867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of self-expanding removable metal esophageal stents during neoadjuvant chemotherapy for resectable esophageal cancer.
    Pellen MG; Sabri S; Razack A; Gilani SQ; Jain PK
    Dis Esophagus; 2012 Jan; 25(1):48-53. PubMed ID: 21595778
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of Survival in Esophageal Squamous Cell Carcinoma with Pathologic Major Response after Neoadjuvant Chemoradiation Therapy and Surgery: The Impact of Chemotherapy Protocols.
    Li CY; Huang PM; Chu PY; Chen PM; Lin MW; Kuo SW; Lee JM
    Biomed Res Int; 2016; 2016():6423297. PubMed ID: 27777949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic impact of the psoas muscle index, a parameter of sarcopenia, in patients with diffuse large B-cell lymphoma treated with rituximab-based chemoimmunotherapy.
    Iltar U; Sözel H; Sözel YK; Ataş Ü; Yücel OK; Salim O; Aydin F; Undar L
    Leuk Lymphoma; 2021 May; 62(5):1098-1106. PubMed ID: 33300380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.